J&J's Caplyta meets main goal of bipolar mania study

People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.

People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025. (REUTERS/Maxim Shemetov)


1 photo
Save Story

Estimated read time: 1-2 minutes

Sept 21 — Johnson & Johnson said on Monday its experimental use of Caplyta ​for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to ‌expanding beyond its currently approved uses.

J&J gained Caplyta through its $14.6 billion acquisition of ⁠Intra-Cellular Therapies last year ​to bolster its neuroscience business.

• ⁠Caplyta significantly reduced symptoms of bipolar mania compared with placebo ‌in the late-stage ‌trial, meeting the study's main goal, J&J said.

• Symptoms ⁠of mania can include grandiosity, ⁠decreased need for sleep, racing thoughts, distractibility, and risk-taking behavior.

• Patients showed improvement as early as three days after starting treatment with the drug, with benefits maintained through the study's three-week duration, according to the company.

• The study ‌also met a key secondary goal ​measuring overall severity of illness, J&J said.

• About 46% of patients treated with Caplyta achieved a clinical response, compared with about 21% of patients who received placebo, the company said.

• The trial evaluated a once-daily 42-milligram dose of Caplyta in adults experiencing manic episodes associated with bipolar ​I disorder.

• J&J's Caplyta is already approved in the United States ‌for depressive episodes ‌associated ⁠with bipolar I and bipolar II disorder and schizophrenia.

• Bipolar disorder affects an estimated 37 million people worldwide. Mania, a defining feature of bipolar I disorder, is marked by unusually ‌elevated or irritable mood ​and increased energy or activity levels ‌that often occur ⁠alongside depressive ​episodes, according to J&J.

(Reporting by Sahil Pandey in Bengaluru; Editing by ​Shailesh Kuber)

Photos

Most recent Lifestyle stories

Related topics

STAY IN THE KNOW

Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Notice.
Newsletter Signup

KSL Weather Forecast

KSL Weather Forecast
Play button